Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"ERα positive breast cancer"”.
-
Novel insights into the molecular mechanisms of endocrine resistance in ERα positive breast cancer
ERα transcriptional activity drives tumour development and metastasis in more than 70% of breast cancer cases. Tamoxifen is the most widely and successfully used endocrine treatment for pre-menopausal women with ERα positive breast cancer. However, subgroups of patients are resistant to this drug. …
-
Identification of novel biomarkers for clinical prognosis in breast cancer
… signalling is up-regulated in numerous human cancers (e.g. stomach cancer, colon, rectal, glioblastoma, ovarian, renal, lung and breast) making S1P signalling an important candidate as a biomarker and a key player in promoting cancer progression. Several inhibitors of SK/S1P signalling pathway …
-
Investigating upstream regulators of FOXA1 in breast cancer
… nuclear receptors, such as estrogen receptor α (ERα) to enhancer regions, it is highly implicated in ERα positive breast cancer. Structural predictions of FOXA1 suggest a highly disordered structure with no clear pockets for rational drug design, making small-molecule inhibition challenging. The …
-
Identifying new actions of estrogen receptor targetable with small molecules
Estrogens, acting via estrogen receptor α (ERα), stimulate the proliferation and metastatic potential of breast cancers, and likely some ovarian, endometrial, and cervical cancers. Endocrine therapy targeting these cancers often leads to development of resistance. Ovarian cancers do not respond to …
-
The anticipatory unfolded protein response and estrogen receptor mutations in breast cancer
Estrogen, acting via estrogen receptor α (ERα), stimulates cancer cell proliferation and metastasis. Endocrine therapy targeting E2:ERα activity often leads to development of antiestrogen resistance. Approximately 30% of patients who have metastatic endocrine therapy resistant breast cancer express …